Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Ixabepilone
Therapeutic Area: Oncology Product Name: Ixempra
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Negma Group
Deal Size: $11.7 million Upfront Cash: Undisclosed
Deal Type: Financing November 05, 2020
Details:
This financing, under the called tranche, serves as a foundation to provide financial resources for the Company to continue execution of its strategy to further progress development of its three high-priority pipeline programs, including IXEMPRA®, stenoparib and dovitinib.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Daratumumab
Therapeutic Area: Oncology Product Name: Darzalex
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Janssen Pharmaceutical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2020
Details:
Second part of the Phase 3 CASSIOPEIA study of daratumumab as maintenance treatment for patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant met the primary endpoint of progression-free survival at a pre-planned interim analysis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Daratumumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Janssen Ortho LLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 22, 2020
Details:
The license agreement terms for Janssen Biotech, Inc. to develop, manufacture and market DARZALEX under the exclusive worldwide license.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
